- Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis2017 | 1. lékařská fakulta
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | 1. lékařská fakulta, 2. lékařská fakulta
- Efektivita prodlouženého dávkovacího intervalu natalizumabu u pacientů s roztroušenou sklerózou2020 | 2. lékařská fakulta
- Srovnání účinnosti subkutánně podávaného interferonu β-1a 44 μg, dimetyl fumarátu a fingolimodu v reálné klinické praxi - multicentrická observační studie2018 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis2015 | 1. lékařská fakulta
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis2012 | 1. lékařská fakulta
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis2012 | 2. lékařská fakulta
- Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis2016 | 1. lékařská fakulta
- Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis2017 | 1. lékařská fakulta
- Alemtuzumab v léčbě roztroušené sklerózy2015 | 2. lékařská fakulta
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis2010 | 2. lékařská fakulta
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial2021 | 1. lékařská fakulta
- Delay from treatment start to full effect of immunotherapies for multiple sclerosis2020 | 1. lékařská fakulta
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod2018 | 1. lékařská fakulta
- Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity2023 | 1. lékařská fakulta
- Perorální kladribin v léčbě roztroušené sklerózy - data z celostátního registru ReMuS(R)2021 | 1. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Hradci Králové, Lékařská fakulta v Plzni
- Is breastfeeding in MS harmful or not? An answer from real-world Czech data2023 | 1. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Hradci Králové, Lékařská fakulta v Plzni, 3. lékařská fakulta
- COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark2024 | 1. lékařská fakulta
- Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis2016 | 1. lékařská fakulta
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study2019 | 1. lékařská fakulta
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial2022 | 1. lékařská fakulta
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry2023 | 1. lékařská fakulta
- Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS2012 | 1. lékařská fakulta
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study2013 | 1. lékařská fakulta
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis2014 | 1. lékařská fakulta
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis2015 | 1. lékařská fakulta
- Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS2016 | 1. lékařská fakulta
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study2017 | 1. lékařská fakulta
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study2020 | 1. lékařská fakulta
- Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS2021 | 2. lékařská fakulta, Lékařská fakulta v Hradci Králové, Lékařská fakulta v Plzni, 3. lékařská fakulta
